The anticipated growth is mainly driven by ten new pipeline drugs expected to be introduced to the market by 2034.

Patients with systemic lupus erythematosus who receive belimumab monotherapy show comparable remission rates and disease control to those who receive combination therapy with immunosuppressants.

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...

Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper ...

SIGLEC‑1 expression correlates with disease activity in patients with lupus erythematosus during type I interferon blockade ...

Researchers have developed a novel animal model that fundamentally changes the understanding of lupus, a complex autoimmune disease. They demonstrate for the first time that a defect in skin cells can ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2 trial for discoid lupus ...

A new study looked at the possibility of a causal relationship between interleukin-18 (IL-18) cytokine and the risk of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE).

Discrimination was linked to increased systemic lupus erythematosus symptom burden, mediated by symptoms of depression and ...